Gaudium IVF IPO Subscription Status Day 2: Fully Subscribed; Retail, NII Lead; GMP, and Other Key Details
- 23rd February 2026
- 07:00 PM
- 2 min read
Summary
Gaudium IVF IPO was fully subscribed on Day 2 of bidding, led by strong demand from Retail and Non-Institutional Investors, while QIB participation remained muted. As of today, the IPO GMP is ₹5. The ₹165 crore issue closes on February 24.Mumbai | February 23
The initial public offering (IPO) of Gaudium IVF & Women Health Ltd was subscribed 3 times as of 5:00 PM on Day 2, according to exchange data. Strong demand from Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs) supported the overall book, while institutional participation remained weak.
Gaudium IVF IPO Subscription Status: Day 2
Total Subscription: 3.00X
- Qualified Institutional Buyers (QIBs):02X
- Non-Institutional Investors (NIIs):62X
- Retail Individual Investors (RIIs):00X
Gaudium IVF IPO GMP Today
As of February 23, 5:00 PM, Gaudium IVF IPO GMP stood at ₹5.
With the upper price band fixed at ₹79 per share, the estimated listing price works out to ₹84, indicating a potential gain of around 6.3%
Note : Grey Market Premium data is unofficial and may not reflect actual listing performance.
To apply for this IPO, click here.
Price Band, Issue Size and Key Details
- Price Band: ₹75–₹79 per share
- Issue Size: ₹165 crore (Fresh Issue: ₹90 crore, OFS: ₹75 crore)
- Lot Size: 189 shares
- Minimum Investment: ₹14,931
- Basis of Allotment: February 25, 2026
The IPO opened on February 20 and will close on February 24. Shares are proposed to list on BSE and NSE on February 27.
Half of the net issue is reserved for QIBs, 15% for NIIs and 35% for retail investors.
Prior to opening, the company raised ₹49.5 crore from anchor investors at ₹79 per share.
Use of IPO Proceeds
The company plans to utilise fresh issue proceeds for:
- Setting up 19 new IVF centres – ₹50 crore
- Prepayment of borrowings – ₹20 crore
- General corporate purposes
Financial Performance:
Gaudium IVF reported revenue of ₹70.96 crore in FY25, up from ₹48.15 crore in FY24. Profit after tax rose to ₹19.13 crore from ₹10.32 crore a year earlier, while EBITDA stood at ₹28.63 crore with margins above 40%. The company reported a Return on Equity (ROE) of 41.31% as of March 2025.
About the Company:
Incorporated in 2015, Gaudium IVF & Women Health Ltd provides in vitro fertilisation (IVF) and assisted reproductive technology (ART) services. The company operates a hub-and-spoke model with 7 full-service hubs and 28 spoke centres across more than 30 locations in India. Led by founder Dr Manika Khanna, it offers IVF, ICSI, IUI, egg freezing and related fertility treatments, catering to both domestic and medical tourism patients.
For more IPO updates, follow PL Capital.
